B+
Bull case
20%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
ELTX
Elicio TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Q2 update restores some optionality through a $15 million financing, stated runway into Q1 2027, a planned Q4 combination study, multiple reported complete responses, and activation of the MSK-led trial. Positive combination data or a credible R0-focused development path could produce asymmetric upside, but the clinical observations remain early and company-reported.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.7.
What can break
A delay or weak signal from the planned Q4 2026 combination study could pressure the stock materially.
Momentum
2
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $5.00 · Bear $0.95Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.90
Why
Momentum2 · Δ7d +0.0
Value41 · Δ7d -0.0
Sentiment68 · Δ7d +11.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.7.
Contradictions & invalidation
- • A delay or weak signal from the planned Q4 2026 combination study could pressure the stock materially.
- • AMPLIFY-7P missed its primary endpoint, weakening the original development thesis.
- • The central Phase 2 AMPLIFY-7P study missed its primary endpoint, leaving the registrational thesis dependent on subgroup interpretation, regulatory acceptance, future funding, and successful execution.
Catalyst clock
2026-12-31
Q4 2026 ELI-002 7P combination-trial start
Lead driver: Sentiment · See AI snapshot
Momentum
2
9% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
68
62% active weight
Current posture
7d trendImproving
Δ7d
+11.7
Δ21d
+21.8
Why this grade
Composite grade C. Momentum 1.5 / Value 41.2 / Sentiment 67.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$79.37M
Beta
-
Shares Out
23.47M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.60
Rev YoY
-100.0%
EPS YoY
-35.1%
Gross Margin
+62.3%
Op Margin
-
Net Debt
-$4.05M
Current Ratio
2.77
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data